Biosimilars Dodge State Roadblocks, But Big Hurdles Remain

Law360, New York (June 5, 2013, 7:08 PM EDT) -- The once-promising biosimilars industry is finally getting some good news as state lawmakers largely balk at bills designed to curtail access to the cheaper versions of pricey brand-name biologic drugs, but experts caution that bruising legislative fights and a daunting regulatory approval process lie ahead.

The 18 bills introduced this year would have thrown an array of pharmacy-level roadblocks in the way of biosimilars. But just one, in North Dakota, appears to have made it through as advocated by Amgen Inc. and Genentech Inc., producers of high-cost biologic...
To view the full article, register now.